GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

Original reporting
Published Nov 18, 2026, 10:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK wins early FDA approval for lung cancer drug Nelkarmi — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The approval reduces regulatory uncertainty and highlights differentiated design goals (treatment resistance, tolerability, and brain metastasis activity), which can shift expectations for GSK’s oncology portfolio trajectory.

02

Market read

A concrete FDA approval with specific response-rate figures is a direct catalyst for GSK’s oncology valuation narrative.

03

What to watch

Commercial impact depends on uptake, competitive positioning versus current ALK inhibitor standards, and whether ongoing filings in other markets translate into timely approvals and label expansion.

Relevance 7/10Novelty 4/10Timing: reported pre-market/early session (10:11 GMT) with immediate regulatory headline impact

Background

The FDA approval is described as early relative to the original decision deadline and is tied to ALKOVE-1 Phase I/II results in patients previously treated with ALK inhibitors.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK won early FDA approval for Nelkarmi, citing ALKOVE-1 Phase I/II data and response rates in previously treated ALK-positive lung cancer patients.

Expected impact

Likely upward bias as the market prices in reduced regulatory risk and potential uptake for an ALK-positive lung cancer therapy with activity including brain metastases.

Evidence & confidence

The article reports a specific FDA approval event ahead of the original deadline, supported by trial response metrics and prior Breakthrough Therapy and Orphan Drug designations.

Market effects

Reinforces FDA receptivity to next-generation ALK inhibitors and may support sentiment for oncology pipeline read-throughs among peers targeting ALK-positive NSCLC.

Could modestly lift UK pharma sentiment given GSK is FTSE 100-listed, though the catalyst is FDA-specific.

May increase global investor focus on ALK-positive lung cancer treatment sequencing and brain-metastasis efficacy claims.

Counterpoint

Approval based on Phase I/II data may still leave uncertainty around confirmatory Phase III outcomes, durability, and real-world adoption versus existing ALK inhibitors.

Key entities

  • GSK

    FTSE 100-listed firm receiving early FDA approval for Nelkarmi.

  • Nelkarmi

    Next-generation lung cancer drug for ALK-positive disease, approved based on ALKOVE-1 data.

  • FDA

    Granted early approval ahead of the original decision deadline.

  • ALKOVE-1

    Phase I/II trial cited for clinically meaningful and durable responses.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.

$GSKMed

FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).